Table 2

Serum autoantibodies in SLE-patients

AntibodySeropositivity n (%)
CA or CC
AAP valueOR (95% CI)
IgM aCL10 (19%)96 (22%)ns0.85 (0.44 to 1.65)
IgG aCL11 (20%)78 (18%)ns1.20 (0.63 to 2.29)
IgG anti-β2GPI9 (17%)91 (21%)ns0.84 (0.43 to 1.68)
IgG PT4 (7%)56 (13%)ns0.69 (0.27 to 1.73)
IgG anti-CCP4 (24%)8 (4%)1.39×10−24.56 (1.36 to15.26)
IgG anti-CAP2 (12%)12 (7%)ns1.60 (0.37 to 6.92)
ANA115 (96%)850 (99%)ns0.40 (0.16 to 1.04)
anti-dsDNA53 (61%)421 (62%)ns1.50 (0.17 to 13.10)
anti-Sm14 (16%)79 (12%)ns0.98 (0.64 to 1.50)
  • Serum anti-CL, anti-β2-GPI and anti-PT were analysed in 490 patients (54 CA/CC and 436 AA) where all have data for anti-CL IgG and anti-prothrombin, 488 patients (54 CA/CC and 434 AA) have data for anti-CL IgM and 489 patients (53 CA/CC and 436 AA) have anti-β2-GP1 data. Serum anti-CCP and anti-CAP were measured by ELISA in 195 patients (17 CA/CC and 178 AA). ANA, anti-dsDNA and anti-Sm were measured according to the diagnosis criteria of American College of Rheumatology. Data for ANA were available from 982 patients (120 CA/CC and 862 AA) and anti-dsDNA and anti-Sm data was available from 761 patients (87 CA/CC and 674 AA). CA or CC indicate rs2230926 risk allele.

  • ANA, anti-nuclear antibodies; anti-Sm, anti-Smith antibodies; β2-GPI, β2 glycoprotein-I; CCP, cyclic citrullinated peptide (pos≥25 U/mL); CL, cardiolipin; dsDNA, double-stranded DNA; ns, non-significant; PT, prothrombin; SLE, systemic lupus erythematosus.